Sunovion scores on PhIII Parkinson's study, shooting for showdown with Acorda; Puma out-licenses neratinib to Israeli biotech
→ Sunovion Pharmaceuticals has posted positive top-line data from their Phase III study for OFF episodes of Parkinson’s disease. According to researchers apomorphine hit …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
